Brief: T2 Biosystems Announces Q4 And Full Year 2022 Financial Results
13/03/2023 20:11
March 13 (Reuters) - T2 Biosystems Inc TTOO.O :
* T2 BIOSYSTEMS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2022
FINANCIAL RESULTS
* T2 BIOSYSTEMS INC Q4 LOSS PER SHARE $1.41
* T2 BIOSYSTEMS INC - EXPECTS FULL YEAR 2023 TOTAL SEPSIS
AND
RELATED PRODUCT REVENUE OF $11.0 MILLION TO $13.0 MILLION
* T2 BIOSYSTEMS INC - GIVEN FOCUS ON PRODUCT REVENUE,
COMPANY IS
NOT PROVIDING GUIDANCE ON RESEARCH AND CONTRIBUTION REVENUE
* T2 BIOSYSTEMS INC Q4 REVENUE FELL 21 PERCENT TO $5.5
MILLION
Source text for Eikon: ID:nGNXc7HCky
Further company coverage: TTOO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on T2 Biosystems
See all newsBrief: T2 Biosystems Announces Intent To Wind Down Operations
Brief: T2 Biosystems Enters Amendment No. 12 To Term Loan Agreement
Brief: T2 Biosystems Announces Exclusive US Agreement With Cardinal Health To Sell Its FDA-Cleared Direct-From-Blood Diagnostics For Rapid Detection Of Sepsis-Causing Pathogens
T2 Biosystems Inc reports results for the quarter ended in June - Earnings Summary
Brief: T2 Biosystems Announces Commercial Expansion Through Malaysia And Indonesia Distributor